The development of a drug for the treatment of corona in Pakistan has entered a critical phase and the successful clinical trials of the Dow University of Health Sciences Code-19 medicine are beginning to yield very positive results.
According to the Dow University of Health Sciences, successful clinical trials of the university’s Code-19 drug interventional immunoglobulin (CIVIG) are beginning to yield very positive results.
The recovery rate of critically ill patients included in the clinical trial was 100%, while the recovery rate of critically ill patients admitted in ICU was more than 60% while 50% of the recovered patients were discharged from the hospital in just 5 days.
It may be recalled that the pre-clinical trials of CIVIG at Dow University began in early April and the Drug Regulatory Authority of Pakistan (DRAP) immediately approved its clinical trials.
The basic funding for the CIVIG preparation project was provided by Dow University of Health Sciences in collaboration with the Higher Education Commission, while Dr. Shaukat Ali and his team under the supervision of the University’s Vice Chancellor Prof. Muhammad Saeed Qureshi provided CIV. Started work on VIG project.
Dr. Shaukat Ali told the media that CIV vaccine is prepared by separating the antibodies obtained from the plasma of healthy patients from Corona.
He said the effectiveness of CIVIG in such patients was a significant achievement and that corona patients had been asked to donate plasma.
He said that the Sindh Blood Transfusion Authority had also given special permission in this regard. However, as the wave of corona is accelerating, it will not be possible to produce the required amount of medicine as plasma is to be donated. The trend is low.
Dr. Shaukat Ali added that the average age of the patients in the clinical trial was 60 years and almost all of them were suffering from diabetes, high blood pressure and heart disease which put their lives at high risk. – The effectiveness of IVIG is a very important achievement.